Guardant Health and Nuvalent entered a multi-year strategic collaboration to develop and potentially commercialize oncology companion diagnostics using Guardant’s tissue and liquid biopsy assets. The partnership will support Nuvalent’s global clinical studies and evaluate Guardant assays as potential companion diagnostic strategies tied to Nuvalent’s investigational ALK inhibitor neladalkib and other pipeline programs.